Want to see TSE:PCLO full AI Analyst Report?
Top Page
PharmaCielo
(PCLO)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.06
▲(52.50% Upside)
Action:Reiterated
Date:07/16/26
The score is driven primarily by weak financial performance—declining revenue, heavy ongoing losses, negative equity, high leverage, and continued negative free cash flow. Technical indicators add a mildly bearish tilt with the stock below key moving averages and a negative MACD. Valuation provides limited support because the negative P/E reflects ongoing unprofitability and no dividend yield data is available.
Positive Factors
Low-cost production hub
Operating in Colombia provides structural cost and agronomic advantages for cultivation and extraction, enabling competitive unit economics for pharmaceutical and wellness customers. This geographic footprint supports long-term margin recovery potential once scale and regulatory approvals align.
Negative Factors
Declining revenue
Sustained revenue decline and volatile sales hinder the firm's ability to absorb fixed costs and leverage its production base. Without stable, growing top-line demand, margins and cash generation may not improve sufficiently to reach breakeven, prolonging capital needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-cost production hub
Operating in Colombia provides structural cost and agronomic advantages for cultivation and extraction, enabling competitive unit economics for pharmaceutical and wellness customers. This geographic footprint supports long-term margin recovery potential once scale and regulatory approvals align.
Read all positive factors
PharmaCielo (PCLO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$11.16M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-3.21
Revenue Growth-25.05%
EPS Growth67.74%
CountryCA
Employees268
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.03
Shares Outstanding211,283,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmaCielo Business Overview & Revenue Model
Company Description
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated med...
How the Company Makes Money
null...
PharmaCielo Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.61M | 3.48M | 1.54M | 5.31M | 1.94M |
| Gross Profit | 756.40K | 730.88K | -1.37M | 827.06K | -4.31M |
| EBITDA | -1.00M | -4.60M | -12.19M | -10.50M | -24.84M |
| Net Income | -4.55M | -9.14M | -16.30M | -16.04M | -26.92M |
Balance Sheet | |||||
| Total Assets | 8.56M | 18.39M | 22.29M | 25.12M | 35.96M |
| Cash, Cash Equivalents and Short-Term Investments | 289.24K | 147.94K | 62.18K | 325.98K | 5.63M |
| Total Debt | 18.65M | 20.52M | 18.31M | 12.59M | 8.43M |
| Total Liabilities | 23.92M | 25.91M | 23.97M | 18.72M | 16.63M |
| Stockholders Equity | -15.35M | -7.52M | -1.68M | 6.39M | 19.33M |
Cash Flow | |||||
| Free Cash Flow | -1.02M | -1.97M | -5.17M | -10.23M | -21.21M |
| Operating Cash Flow | -1.02M | -1.97M | -5.15M | -9.71M | -20.07M |
| Investing Cash Flow | 6.66M | 41.14K | 391.64K | -725.49K | -1.66M |
| Financing Cash Flow | -5.52M | 2.02M | 4.63M | 5.30M | 18.21M |
PharmaCielo Technical Analysis
Negative
0.04
Price Trends
0.08
Negative
0.07
Negative
0.06
Positive
Market Momentum
>-0.01
Positive
42.29
Neutral
13.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PCLO, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.29 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PCLO.
PharmaCielo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | C$8.50M | -5.29 | 11.57% | ― | -16.08% | -547.37% | |
54 Neutral | C$33.14M | -3.86 | -19.10% | ― | 0.66% | -14.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$45.79M | -0.76 | -19.76% | ― | -100.00% | 87.93% | |
46 Neutral | C$14.40M | -6.89 | -71.80% | ― | -17.50% | -120.67% | |
44 Neutral | C$11.16M | -2.39 | ― | ― | -25.05% | 67.74% | |
41 Neutral | C$15.72M | -4.08 | -68.32% | ― | 1.96% | -24.60% |
* Healthcare Sector Average
TSE:PCLO
PharmaCielo
0.06
<0.01
20.00%
TSE:ATLE
Willow Biosciences Inc
0.14
-0.06
-31.82%
TSE:LABS
MediPharm Labs
0.08
0.02
23.08%
TSE:OILS
Nextleaf Solutions
0.05
-0.02
-25.00%
TSE:AVCN
Avicanna
0.13
-0.16
-55.36%
TSE:INNO
InnoCan Pharma
3.20
-10.45
-76.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.